- Itamar Medical (NASDAQ:ITMR) +44% on being taken over by Zoll Medical for ~$538M
- Leap Therapeutics (NASDAQ:LPTX) +42% to present new data from the DisTinGuish study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congres
- BELLUS Health (NASDAQ:BLU) +24% positive interim findings from trial for patients with chronic cough
- Aterian (NASDAQ:ATER) +21%.
- REGENXBIO (NASDAQ:RGNX) +19% AbbVie and REGENXBIO team up for eye disease therapy in $1.5 billion deal
- Hepion Pharmaceuticals (NASDAQ:HEPA) +18% additional data from Hepion Pharmaceuticals’ phase 2a ‘AMBITION’ rial further strengthens CRV431 clinical profile and paves way for initiation of Phase 2b ‘ASCEND-NASH’ clinical program
- Grupo Financiero Galicia (NASDAQ:GGAL) +15%.
- Pampa Energia (NYSE:PAM) +15%.
- Central Puerto (NYSE:CEPU) +13%.
- Grupo Supervielle (NYSE:SUPV) +13%.
- Banco Macro (NYSE:BMA) +12%.
- YPF Sociedad Anonima (NYSE:YPF) +10%.
- Telecom Argentina (NYSE:TEO) +10%.
- Transportadora de Gas del Sur (NYSE:TGS) +10%.
- Uranium Royalty (NASDAQ:UROY) +10%.
- Virpax Pharmaceuticals (NASDAQ:VRPX) +9%.
- Glory Star New Media (NASDAQ:GSMG) +8%.
- aTyr Pharma (NASDAQ:LIFE) +8% after success for lead asset in trial for lung disease
- InMed Pharmaceuticals (NASDAQ:INM) +8%.
- Document Security Systems (NYSE:DSS) +7%.
- Aluminum Corporation of China (NYSE:ACH) +7%.
- The Honest (NASDAQ:HNST) +7%.
- Uranium Energy (NYSE:UEC) +7%.
- Verona Pharma (NASDAQ:VRNA) +6%.